Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369: Mini-assessment Report

Abstract

This contracted mini assessment examines the evidence to the support listing of 68Gallium-1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid-peptide (68Ga-DOTA-peptide) positron emission tomography (PET) / computed tomography (CT) scanning for the diagnosis of gastroenteropancreatic neuroendocrine tumours (GEP NETs) on the Medicare Benefits Schedule (MBS). The target population are people with clinically suspected GEP NETs. The applicant has claimed that the successful listing of the technology in the target population and setting will lead to a reduction in the number of repeated tests and superior safety in terms of faster acquisition time and lower radiation exposure. A systematic literature review was not undertaken for this mini-assessment; and therefore, the evidence base is incomplete. No comparative studies were identified to inform on therapeutic efficacy or effectiveness